Post-traumatic Stress Disorder Treatment Market Worth $1.4 Billion By 2030

Post-traumatic Stress Disorder Treatment Market Growth & Trends

The global post-traumatic stress disorder treatment market size is expected to reach USD 1.4 billion by 2030, registering a CAGR of 4.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The increasing disease burden of post-traumatic stress disorder (PTSD), innovation in R&D and emerging drug pipeline, and efforts by government and non-profit organizations to increase awareness are the key factors augmenting the space growth.

The emerging drug pipeline, thereby, expected advancement and drug launches for the treatment of PTSD, is anticipated to offer a lucrative opportunity for market growth over the forecast period. This can be attributed to the presence of Aptinyx’s NYX-783, Bionomics’ BNC210, and Jazz Pharmaceuticals’ JZP150 under phase 2 clinical trials. Ahead of these, Otsuka Pharmaceutical’s Brexpiprazole and Zoloft Combination are in phase 3 trial, creating fierce competition among key players to launch the product in the space.

Events such as the COVID-19 pandemic further support space growth. Several studies have been conducted to understand the impact of the covid 19 pandemic on mental health, increasing the risk of PTSD and rising demand for its treatment. For instance, the August 2021 review article, "COVID?19 and Post traumatic Stress Disorder: The Perfect 'Storm' for Mental Health," clearly demonstrates an increase in the risk of development of PTSD among pandemic affected families and survivors.

Companies are strategically taking initiatives that aid in developing new products, regulatory approvals, and enhancing their product portfolio with geographical expansion. For instance, in March 2022, H. Lundbeck A/S granted the license agreement to Sun Pharmaceutical Industries Ltd., for marketing and distribute of Vortioxetine under the brand name Vortidiftm in the Indian market. 

 Request a free sample copy or view report summary: Post-traumatic Stress Disorder Treatment Market Report

Post-traumatic Stress Disorder Treatment Market Report Highlights 

• In 2021, antidepressants segment accounted for the largest share and is anticipated to maintain its position over the forecast period owing to FDA approved SSRIs such as Zoloft (sertraline) and Paxil (paroxetine)

• Based on demographics, adult segment is estimated to witness the fastest CAGR of 5.1% during the forecast period owing to presence of rising disorder incidence in adult group, major chunk of patients in this age group and increase in traumatic experiences

• Based on distribution channel, retail pharmacy segment dominated the space in 2021, due to factors such easy of availability, and its compatibility with homecare setting for the long term treatment

• Asia Pacific region is anticipated to experience the fastest growth over the forecast period due to an increased awareness among the population, rise in disposable income, and high disease prevalence of PTSD in developing countries 

Post-traumatic Stress Disorder Treatment Market Segmentation

Grand View Research has segmented the post-traumatic stress disorder treatment market on the basis of drug class, demographics, distribution channel, and region: 

PTSD Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Antidepressants

• Antipsychotics

• Anti-anxiety

• Others

PTSD Treatment Demographics Outlook (Revenue, USD Million, 2018 - 2030)

• Adult

• Children

PTSD Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Others

PTSD Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S

• Canada

• Europe

• U.K.

• Germany

• France

• Italy

• Spain

• Asia Pacific

• India

• China

• Japan

• Australia

• South Korea

• Latin America

• Argentina

• Brazil

• Mexico

• Middle East & Africa

• Saudi Arabia

• South Africa

• UAE 

List of Key Players of Post-traumatic Stress Disorder (PTSD) Treatment Market

• Lupin Limited

• Pfizer, Inc.

• Aurobindo Pharma Limited

• Merck KGaA

• GlaxoSmithKline plc.

• Otsuka Pharmaceutical Development

• Jazz Pharmaceuticals

• Bionomics

• Aptinyx         

• AstraZeneca